NASD · Healthcare · Pharmaceutical Retailers · USA
Petmed Express Inc is a micro cap company (market value under $300 million) in the Pharmaceutical Retailers industry.
PetMed Express operates as a direct-to-consumer online pet pharmacy providing prescription medications, generic drugs, over-the-counter products, and pet food to customers across the United States through websites, mobile applications, and contact centers. The company serves cats, dogs, and horses, addressing conditions including allergies, arthritis, and anxiety.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Petmed Express Inc stock.
No reliable verdict: intrinsic value $7.23 per share, market price $1.19 (as of 2026-10-30).
Its earnings through the cycle, capitalised at its cost of capital, would put the shares at $7.23: 6 times the price of $1.19. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
6 more funds hold it; the full list is part of the paid plan.
We do not publish a verdict on PETS. Its earnings through the cycle, capitalised at its cost of capital, would put the shares at $7.23: 6 times the price of $1.19. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
We do not publish one (as of the 2026-10-30 close). Its earnings through the cycle, capitalised at its cost of capital, would put the shares at $7.23: 6 times the price of $1.19. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.